The EH2_P_AH0_D_EH2_M_IY0_AA1_L_AH0_JH_IY0 AH1_V HH_ER1_P_IY0_Z S_IH1_M_P_L_EH2_K_S IH1_Z AH1_V S_AH0_B_S_T_AE1_N_SH_AH0_L epidemiologic AH0_N_D P_AH1_B_L_IH0_K HH_EH1_L_TH IH1_N_T_AH0_R_EH2_S_T Worldwide    DH_AH0 R_EY1_T AH1_V IH2_N_F_EH1_K_SH_AH0_N W_IH1_DH HH_ER1_P_IY0_Z S_IH1_M_P_L_EH2_K_S V_AY1_R_AH0_S K_AW1_N_T_IH0_NG B_OW1_TH HSV AH0_N_D HSV IH1_Z ER0_AW1_N_D 90     Although M_EH1_N_IY0 P_IY1_P_AH0_L IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV D_IH0_V_EH1_L_AH0_P labial AO1_R JH_EH1_N_AH0_T_AH0_L L_IY1_ZH_AH0_N_Z    HH_ER1_P_IY0_Z S_IH1_M_P_L_EH2_K_S     DH_AH0 M_AH0_JH_AO1_R_AH0_T_IY0 AA1_R IY1_DH_ER0 AH0_N_D_AY1_AE0_G_N_OW0_S_T AO1_R D_IH0_S_P_L_EY1 N_OW1 F_IH1_Z_IH0_K_AH0_L S_IH1_M_P_T_AH0_M_Z IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z W_IH1_DH N_OW1 S_IH1_M_P_T_AH0_M_Z AA1_R D_IH0_S_K_R_AY1_B_D AE1_Z EY2_S_IH2_M_P_T_AH0_M_AE1_T_IH0_K AO1_R AE1_Z HH_AE1_V_IH0_NG subclinical HH_ER1_P_IY0_Z    In M_EH1_N_IY0 IH2_N_F_EH1_K_SH_AH0_N_Z    DH_AH0 F_ER1_S_T S_IH1_M_P_T_AH0_M AH0 P_ER1_S_AH0_N W_IH1_L HH_AE1_V AH1_V DH_EH1_R OW1_N IH2_N_F_EH1_K_SH_AH0_N IH1_Z DH_AH0 HH_AO2_R_AH0_Z_AA1_N_T_AH0_L T_R_AE0_N_S_M_IH1_SH_AH0_N T_UW1 AH0 S_EH1_K_SH_UW0_AH0_L P_AA1_R_T_N_ER0 AO1_R DH_AH0 V_ER1_T_IH0_K_AH0_L T_R_AE0_N_S_M_IH1_SH_AH0_N AH1_V N_IY2_OW0_N_EY1_T_AH0_L HH_ER1_P_IY0_Z T_UW1 AH0 N_UW1_B_AO0_R_N AE1_T T_ER1_M Since M_OW1_S_T EY2_S_IH2_M_P_T_AH0_M_AE1_T_IH0_K IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z AA1_R AH2_N_AH0_W_EH1_R AH1_V DH_EH1_R IH2_N_F_EH1_K_SH_AH0_N    DH_EY1 AA1_R K_AH0_N_S_IH1_D_ER0_D AE1_T HH_AY1 R_IH1_S_K F_AO1_R S_P_R_EH1_D_IH0_NG HSV    Many S_T_AH1_D_IY0_Z HH_AE1_V B_IH1_N P_ER0_F_AO1_R_M_D ER0_AW1_N_D DH_AH0 W_ER1_L_D T_UW1 EH1_S_T_AH0_M_AH0_T DH_AH0 N_AH1_M_B_ER0_Z AH1_V IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV AH0_N_D HSV B_AY1 D_IH0_T_ER1_M_AH0_N_IH0_NG IH1_F DH_EY1 HH_AE1_V D_IH0_V_EH1_L_AH0_P_T AE1_N_T_IH0_B_AA2_D_IY0_Z AH0_G_EH1_N_S_T IY1_DH_ER0 V_AY1_R_AH0_L S_P_IY1_SH_IY0_Z    This IH2_N_F_AO2_R_M_EY1_SH_AH0_N P_R_AH0_V_AY1_D_Z P_AA2_P_Y_AH0_L_EY1_SH_AH0_N P_R_EH1_V_AH0_L_AH0_N_S AH1_V HSV V_AY1_R_AH0_L IH2_N_F_EH1_K_SH_AH0_N_Z IH0_N IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z W_IH1_DH AO1_R W_IH0_TH_AW1_T AE1_K_T_IH0_V D_IH0_Z_IY1_Z It HH_AE1_Z T_UW1 B_IY1 R_IH0_M_EH1_M_B_ER0_D DH_AE1_T DH_EH1_R AA1_R P_AA2_P_Y_AH0_L_EY1_SH_AH0_N S_AH1_B_G_R_UW2_P_S DH_AE1_T AA1_R M_AO1_R V_AH1_L_N_ER0_AH0_B_AH0_L F_AO1_R HSV IH2_N_F_EH1_K_SH_AH0_N_Z    S_AH1_CH AE1_Z K_AE1_N_S_ER0 K_IY2_M_OW0_TH_EH1_R_AH0_P_IY0 P_EY1_SH_AH0_N_T_S    Large D_IH1_F_ER0_AH0_N_S_IH0_Z IH0_N HSV seroprevalence AA1_R S_IY1_N IH0_N D_IH1_F_ER0_AH0_N_T European K_AH1_N_T_R_IY0_Z HSV seroprevalence IH1_Z HH_AY1 IH0_N Bulgaria    83 %   AH0_N_D The Czech Republic    80 %    AH0_N_D L_OW1_ER0 IH0_N Belgium    67 %    The Netherlands    56 %    AH0_N_D Finland    52 %     The T_IH1_P_AH0_K_AH0_L EY1_JH AE1_T W_IH1_CH HSV IH2_N_F_EH1_K_SH_AH0_N IH1_Z AH0_K_W_AY1_ER0_D R_EY1_N_JH_AH0_Z F_R_AH1_M T_UW1 Y_IH1_R_Z IH0_N Central AH0_N_D Eastern European K_AH1_N_T_R_IY0_Z L_AY1_K Bulgaria AH0_N_D DH_AH0 Czech Republic    T_UW1 OW1_V_ER0 25 Y_IH1_R_Z AH1_V EY1_JH IH0_N Northern European K_AH1_N_T_R_IY0_Z S_AH1_CH AE1_Z Finland    The Netherlands    Germany    AH0_N_D England AH0_N_D Wales Young AH0_D_AH1_L_T_S IH0_N Northern European K_AH1_N_T_R_IY0_Z AA1_R L_EH1_S L_AY1_K_L_IY0 T_UW1 B_IY1 IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV    European W_IH1_M_AH0_N AA1_R M_AO1_R L_AY1_K_L_IY0 T_UW1 B_IY1 HSV seropositive DH_AE1_N M_EH1_N    HSV seropositivity IH1_Z W_AY1_D_L_IY0 D_IH0_S_T_R_IH1_B_Y_AH0_T_AH0_D IH0_N Europeans OW1_L_D_ER0 DH_AE1_N 12    AO2_L_DH_OW1 DH_EH1_R AA1_R L_AA1_R_JH D_IH1_F_ER0_AH0_N_S_IH0_Z IH0_N DH_AH0 P_ER0_S_EH1_N_T_AH0_JH AH1_V DH_AH0 P_AA2_P_Y_AH0_L_EY1_SH_AH0_N IH0_K_S_P_OW1_Z_D T_UW1 HSV Bulgaria HH_AE1_Z AH0 HH_AY1    23 %   HSV seroprevalence R_EH1_L_AH0_T_IH0_V T_UW1 AH1_DH_ER0 European K_AH1_N_T_R_IY0_Z    Germany    13 %    Finland    13 %    Belgium    11 %    The Netherlands    %    DH_AH0 Czech Republic    %    AH0_N_D England AH0_N_D Wales    %     Women AA1_R M_AO1_R L_AY1_K_L_IY0 T_UW1 B_IY1 seropositive DH_AE1_N M_EH1_N    AH0_N_D L_AY1_K_L_IY0 AH0_K_W_AY1_ER0 DH_AH0 V_AY1_R_AH0_S AE1_T AE1_N ER1_L_IY0_ER0 EY1_JH    In IY1_CH K_AH1_N_T_R_IY0 AH1_V Europe    HSV seropositivity B_IH0_K_AH1_M_Z M_AO1_R K_AA1_M_AH0_N F_R_AH1_M AE2_D_AH0_L_EH1_S_AH0_N_S AA1_N_W_ER0_D_Z AH0_N_D IH2_N_K_R_IY1_S_IH0_Z IH0_N DH_AH0 P_AA2_P_Y_AH0_L_EY1_SH_AH0_N W_IH1_DH EY1_JH    W_IH1_DH AH0 D_IH0_K_L_AY1_N IH0_N DH_AH0 OW1_L_D_ER0 EY1_JH G_R_UW1_P_S IH0_N S_AH1_M K_AH1_N_T_R_IY0_Z    The M_OW1_S_T R_IY1_S_AH0_N_T D_EY1_T_AH0 F_AO1_R HSV W_AA1_Z P_AH1_B_L_IH0_SH_T IH0_N March 2010    B_EY1_S_T AA1_N AH0 National Health AH0_N_D Nutrition Examination Survey S_T_AH1_D_IY0 P_ER0_F_AO1_R_M_D B_IH0_T_W_IY1_N 2005 AH0_N_D 2013 B_AY1 CDC About IH0_N Americans    16 %   EY1_JH_D 14 T_UW1 49 IH1_Z IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV HSV P_R_EH1_V_AH0_L_AH0_N_S W_AA1_Z N_IH1_R_L_IY0 T_W_AY1_S AE1_Z HH_AY1 AH0_M_AH1_NG W_IH1_M_AH0_N    20 %   DH_AE1_N M_EH1_N    11 %    AH0_N_D W_AA1_Z M_AO1_R DH_AE1_N TH_R_IY1 T_AY1_M_Z HH_AY1_ER0 AH0_M_AH1_NG B_L_AE1_K_S    39 %   DH_AE1_N N_AA1_N Hispanic W_AY1_T_S    12 %     The M_OW1_S_T AH0_F_EH1_K_T_IH0_D G_R_UW1_P W_AA1_Z B_L_AE1_K W_IH1_M_AH0_N    W_IH1_DH AH0 P_R_EH1_V_AH0_L_AH0_N_S R_EY1_T AH1_V 48 Prevalence IH2_N_K_R_IY1_S_T W_IH1_DH EY1_JH AH0_N_D N_AH1_M_B_ER0 AH1_V P_AA1_R_T_N_ER0_Z Only 18 %  AH1_V DH_OW1_Z IH2_N_F_EH1_K_T_IH0_D HH_AE1_D P_R_IY1_V_IY0_AH0_S_L_IY0 B_IH1_N AH0_W_EH1_R AH1_V DH_EH1_R IH2_N_F_EH1_K_SH_AH0_N    African Americans AH0_N_D IH1_M_AH0_G_R_AH0_N_T_S F_R_AH1_M D_IH0_V_EH1_L_AH0_P_IH0_NG K_AH1_N_T_R_IY0_Z T_IH1_P_IH0_K_L_IY0 HH_AE1_V AE1_N HSV seroprevalance IH0_N DH_EH1_R AE2_D_AH0_L_EH1_S_AH0_N_T P_AA2_P_Y_AH0_L_EY1_SH_AH0_N DH_AE1_T IH1_Z T_UW1 AO1_R TH_R_IY1 T_AY1_M_Z HH_AY1_ER0 DH_AE1_N DH_AE1_T AH1_V Caucasian Americans    Many W_AY1_T Americans B_IH0_K_AH1_M S_EH1_K_SH_UW0_AH0_L_IY0 AE1_K_T_IH0_V W_AY1_L seronegative F_AO1_R HSV The AE1_B_S_AH0_N_S AH1_V AE1_N_T_IH0_B_AA2_D_IY0_Z F_R_AH1_M AH0 P_R_AY1_ER0 AO1_R_AH0_L HSV IH2_N_F_EH1_K_SH_AH0_N L_IY1_V_Z DH_IY1_Z IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z S_AH0_S_EH1_P_T_AH0_B_AH0_L T_UW1 HH_ER1_P_IY0_Z W_IH1_T_L_OW2    HH_ER1_P_IY0_Z gladiatorium    AH0_N_D HSV JH_EH1_N_AH0_T_AH0_L IH2_N_F_EH1_K_SH_AH0_N Primary JH_EH1_N_AH0_T_AH0_L IH2_N_F_EH1_K_SH_AH0_N B_R_IH1_NG_Z W_IH1_DH IH1_T DH_AH0 R_IH1_S_K AH1_V V_ER1_T_IH0_K_AH0_L T_R_AE0_N_S_M_IH1_SH_AH0_N T_UW1 DH_AH0 neonate    AH0_N_D IH1_Z HH_AY1_AH0_S_T IH1_F DH_AH0 M_AH1_DH_ER0 K_AA1_N_T_R_AE2_K_T_S AH0 P_R_AY1_M_EH2_R_IY0 IH2_N_F_EH1_K_SH_AH0_N D_UH1_R_IH0_NG DH_AH0 TH_ER1_D T_R_AY0_M_EH1_S_T_ER0 AH1_V P_R_EH1_G_N_AH0_N_S_IY0 In DH_AH0 DH_AH0 N_AH1_M_B_ER0 AH1_V JH_EH1_N_AH0_T_AH0_L IH2_N_F_EH1_K_SH_AH0_N_Z K_AA1_Z_D B_AY1 HSV IH1_Z N_AW1 TH_AO1_T T_UW1 B_IY1 AH0_B_AW1_T 50 %  AH1_V F_ER1_S_T EH1_P_IH0_S_OW2_D_Z AH1_V JH_EH1_N_AH0_T_AH0_L IH2_N_F_EH1_K_SH_AH0_N     In HH_EH1_L_TH_IY0 AH0_D_AH1_L_T_S    HSV IH2_N_F_EH1_K_SH_AH0_N AH0_K_ER1_Z M_AO1_R F_R_IY1_K_W_AH0_N_T_L_IY0 IH0_N DH_AH0 United States DH_AE1_N IH0_N Europe Seroprevalence R_EY1_T_S IH0_N DH_AH0 United States AH0_P_IH1_R_D T_UW1 B_IY1 IH2_N_K_R_IY1_S_IH0_NG    R_AY1_Z_IH0_NG F_R_AH1_M 16 %  IH0_N 1976 T_UW1 21 %  IH0_N 1994    However    DH_IH1_S T_R_EH1_N_D S_IY1_M_Z T_UW1 HH_AE1_V R_IH0_V_ER1_S_T IH2_T_S_EH1_L_F IH0_N R_IY1_S_AH0_N_T Y_IH1_R_Z    D_R_AA1_P_IH0_NG T_UW1 17 %  IH0_N 2004    The K_ER1_AH0_N_T P_R_EH1_V_AH0_L_AH0_N_S AH1_V JH_EH1_N_AH0_T_AH0_L HH_ER1_P_IY0_Z K_AA1_Z_D B_AY1 HSV IH0_N DH_AH0 IH1_Z R_AH1_F_L_IY0 W_AH1_N IH0_N F_AO1_R AO1_R F_AY1_V AH0_D_AH1_L_T_S    W_IH1_DH AH0_P_R_AA1_K_S_AH0_M_AH0_T_L_IY0 50 M_IH1_L_Y_AH0_N P_IY1_P_AH0_L IH2_N_F_EH1_K_T_IH0_D W_IH1_DH JH_EH1_N_AH0_T_AH0_L HH_ER1_P_IY0_Z AH0_N_D AE1_N EH1_S_T_AH0_M_EY2_T_AH0_D M_IH1_L_Y_AH0_N N_UW1 JH_EH1_N_AH0_T_AH0_L HH_ER1_P_IY0_Z IH2_N_F_EH1_K_SH_AH0_N_Z AH0_K_ER1_IH0_NG IY1_CH Y_IH1_R     African Americans AH0_P_IH1_R M_AO1_R S_AH0_S_EH1_P_T_AH0_B_AH0_L T_UW1 HSV    AO2_L_DH_OW1 DH_AH0 P_R_EH1_Z_AH0_N_S AH1_V AE1_K_T_IH0_V JH_EH1_N_AH0_T_AH0_L S_IH1_M_P_T_AH0_M_Z IH1_Z M_AO1_R L_AY1_K_L_IY0 IH0_N Caucasian Americans    The L_AA1_R_JH_AH0_S_T IH2_N_K_R_IY1_S IH0_N HSV AE2_K_W_AH0_Z_IH1_SH_AH0_N D_UH1_R_IH0_NG DH_AH0 P_AE1_S_T F_Y_UW1 Y_IH1_R_Z IH1_Z IH0_N W_AY1_T AE2_D_AH0_L_EH1_S_AH0_N_T_S    People W_IH1_DH M_EH1_N_IY0 L_AY1_F_T_AY2_M S_EH1_K_SH_UW0_AH0_L P_AA1_R_T_N_ER0_Z AH0_N_D DH_OW1_Z HH_UW1 AA1_R S_EH1_K_SH_UW0_AH0_L_IY0 AE1_K_T_IH0_V F_R_AH1_M AH0 Y_AH1_NG EY1_JH AA1_R AO1_L_S_OW0 AE1_T HH_AY1_ER0 R_IH1_S_K F_AO1_R DH_AH0 T_R_AE0_N_S_M_IH1_SH_AH0_N AH1_V HSV IH0_N DH_AH0       Women AA1_R AE1_T HH_AY1_ER0 R_IH1_S_K DH_AE1_N M_EH1_N F_AO1_R AH0_K_W_AY1_R_IH0_NG HSV IH2_N_F_EH1_K_SH_AH0_N    AH0_N_D DH_AH0 CH_AE1_N_S AH1_V B_IY1_IH0_NG IH2_N_F_EH1_K_T_IH0_D IH2_N_K_R_IY1_S_IH0_Z W_IH1_DH EY1_JH     The CDC R_IH0_P_AO1_R_T_S DH_AE1_T 48 %  AH1_V African American W_IH1_M_AH0_N IH0_N DH_AH0 United States AA1_R IH2_N_F_EH1_K_T_IH0_D W_IH1_DH DH_AH0 HSV V_AY1_R_AH0_S      According T_UW1 AH0 S_T_AH1_D_IY0 IH0_N Ontario    AH1_V P_IY1_P_AH0_L B_IH0_T_W_IY1_N DH_AH0 EY1_JH_IH0_Z AH1_V 15 T_UW1 16    26 %  AH1_V M_EH1_N    32 %  AH1_V N_AA1_N P_R_EH1_G_N_AH0_N_T W_IH1_M_AH0_N    AH0_N_D 55 %  AH1_V P_R_EH1_G_N_AH0_N_T W_IH1_M_AH0_N T_EH1_S_T_IH0_D P_AA1_Z_AH0_T_IH0_V F_AO1_R HSV AE1_N_T_IH0_B_AA2_D_IY0_Z Between DH_AH0 EY1_JH_IH0_Z AH1_V 40 T_UW1 44    54 %  AH1_V M_EH1_N    88 %  AH1_V W_IH1_M_AH0_N    AH0_N_D 69 %  AH1_V P_R_EH1_G_N_AH0_N_T W_IH1_M_AH0_N T_EH1_S_T_IH0_D P_AA1_Z_AH0_T_IH0_V F_AO1_R HSV AE1_N_T_IH0_B_AA2_D_IY0_Z The OW1_V_ER0_AO2_L EY1_JH JH_EH1_N_D_ER0 S_T_AE1_N_D_ER0_D_AY2_Z_D seroprevelance F_AO1_R HSV AE1_N_T_IH0_B_AA2_D_IY0_Z W_AA1_Z 51    Teenagers AA1_R L_EH1_S L_AY1_K_L_IY0 T_UW1 B_IY1 seropositive F_AO1_R HSV AE1_N_T_IH0_B_AA2_D_IY0_Z AH0_G_EH1_N_S_T DH_IH1_S V_AY1_R_AH0_S AA1_R OW1_N_L_IY0 F_AW1_N_D IH0_N %  AH1_V 15 -  AH0_N_D 16 Y_IH1_R OW1_L_D_Z    However    21 %  AH1_V IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z IH0_N DH_EH1_R ER1_L_IY0 F_AO1_R_T_IY0_Z HH_AE1_V AE1_N_T_IH0_B_AA2_D_IY0_Z AH0_G_EH1_N_S_T HSV    R_AH0_F_L_EH1_K_T_IH0_NG DH_AH0 S_EH1_K_SH_UW0_AH0_L_IY0 T_R_AE0_N_S_M_IH1_T_IH0_D N_EY1_CH_ER0 AH1_V DH_IH1_S V_AY1_R_AH0_S When standardising F_AO1_R EY1_JH    HSV seroprevalence IH0_N Ontario F_AO1_R IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z B_IH0_T_W_IY1_N DH_AH0 EY1_JH_IH0_Z AH1_V 15 T_UW1 44 W_AA1_Z    Rates F_AO1_R Canadian P_IY1_P_AH0_L IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV IH1_Z M_AH1_CH L_OW1_ER0 DH_AE1_N EH1_S_T_AH0_M_EY2_T_AH0_D L_EH1_V_AH0_L_Z AH1_V HSV seroprevalence IH0_N P_IY1_P_AH0_L AH1_V AH0 S_IH1_M_AH0_L_ER0 EY1_JH R_EY1_N_JH IH0_N DH_AH0 United States    HSV seroprevalence IH0_N P_R_EH1_G_N_AH0_N_T W_IH1_M_AH0_N B_IH0_T_W_IY1_N DH_AH0 EY1_JH_IH0_Z AH1_V 15 44 IH0_N British Columbia IH1_Z S_IH1_M_AH0_L_ER0    W_IH1_DH 57 %  HH_AE1_V_IH0_NG AE1_N_T_IH0_B_AA2_D_IY0_Z F_AO1_R HSV AH0_N_D 13 %  HH_AE1_V_IH0_NG AE1_N_T_IH0_B_AA2_D_IY0_Z F_AO1_R HSV    In British Columbia IH0_N 1999    DH_AH0 seroprevalence AH1_V HSV AE1_N_T_IH0_B_AA2_D_IY0 IH0_N L_EH1_F_T_OW2_V_ER0 S_IH1_R_AH0_M S_AH0_B_M_IH1_T_AH0_D F_AO1_R antenatal T_EH1_S_T_IH0_NG R_IH0_V_IY1_L_D AH0 P_R_EH1_V_AH0_L_AH0_N_S AH1_V 17 %   R_EY1_N_JH_IH0_NG F_R_AH1_M %  IH0_N W_IH1_M_AH0_N 15 19 Y_IH1_R_Z OW1_L_D T_UW1 28 %  IH0_N DH_OW1_Z 40 44 Y_IH1_R_Z   •  In AH0_T_EH1_N_D_IY1_Z AE1_T AE1_N Alberta S_EH1_K_SH_UW0_AH0_L_IY0 T_R_AE0_N_S_M_IH1_T_IH0_D IH2_N_F_EH1_K_SH_AH0_N    STI    K_L_IH1_N_IH0_K IH0_N 1994 AH0_N_D 1995    DH_AH0 seroprevalence AH1_V HSV AH0_N_D  - IH0_N L_EH1_F_T_OW2_V_ER0 S_IH1_R_AH0 W_AA1_Z 56 %  AH0_N_D 19 %   R_IH0_S_P_EH1_K_T_IH0_V_L_IY0    In Nova Scotia    58 %  AH1_V 790 HSV AY1_S_AH0_L_EY2_T_S F_R_AH1_M JH_EH1_N_AH0_T_AH0_L L_IY1_ZH_AH0_N K_AH1_L_CH_ER0_Z IH0_N W_IH1_M_AH0_N W_ER1 HSV ;  IH0_N M_EH1_N    36 %  AH1_V 468 AY1_S_AH0_L_EY2_T_S W_ER1 HSV    HSV IH1_Z M_AO1_R K_AA1_M_AH0_N IH0_N Sub Saharan Africa DH_AE1_N IH0_N Europe AO1_R DH_AH0 North America Up T_UW1 82 %  AH1_V W_IH1_M_AH0_N AH0_N_D 53 %  AH1_V M_EH1_N IH0_N Sub Saharan Africa AA1_R seropositive F_AO1_R HSV    These AA1_R DH_AH0 HH_AY1_AH0_S_T L_EH1_V_AH0_L_Z AH1_V HSV IH2_N_F_EH1_K_SH_AH0_N IH0_N DH_AH0 W_ER1_L_D    AO2_L_DH_OW1 IH0_G_Z_AE1_K_T L_EH1_V_AH0_L_Z V_EH1_R_IY0 F_R_AH1_M K_AH1_N_T_R_IY0 T_UW1 K_AH1_N_T_R_IY0 IH0_N DH_IH1_S K_AA1_N_T_AH0_N_AH0_N_T    In M_OW1_S_T African K_AH1_N_T_R_IY0_Z    HSV P_R_EH1_V_AH0_L_AH0_N_S IH2_N_K_R_IY1_S_IH0_Z W_IH1_DH EY1_JH However    EY1_JH AH0_S_OW1_S_IY0_EY2_T_AH0_D D_IH0_K_R_IY1_S_AH0_Z IH0_N HSV seroprevalence HH_AE1_Z B_IH1_N AH0_B_Z_ER1_V_D F_AO1_R W_IH1_M_AH0_N IH0_N Uganda AH0_N_D Zambia    AH0_N_D IH0_N M_EH1_N IH0_N Ethiopia    Benin    AH0_N_D Uganda    Genital HH_ER1_P_IY0_Z AH0_P_IH1_R_Z L_EH1_S K_AA1_M_AH0_N IH0_N Northern Africa K_AH0_M_P_EH1_R_D T_UW1 Sub Saharan Africa    For IH0_G_Z_AE1_M_P_AH0_L    OW1_N_L_IY0 26 %  AH1_V M_IH1_D_AH0_L EY1_JH_D W_IH1_M_AH0_N HH_AE1_V AE1_N_T_IH0_B_AA2_D_IY0_Z F_AO1_R HSV IH0_N Morocco     Women AA1_R M_AO1_R L_AY1_K_L_IY0 T_UW1 B_IY1 IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV W_AH1_N_S DH_EY1 AA1_R OW1_V_ER0 DH_AH0 EY1_JH AH1_V 40    Children IH0_N Egypt W_IH1_DH AH0_K_Y_UW1_T L_IH2_M_F_AH0_B_L_AE1_S_T_AH0_K L_UW0_K_IY1_M_IY0_AH0 AA1_R AO1_F_T_AH0_N IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV F_R_AH1_M AH0 Y_AH1_NG EY1_JH HSV AO1_R HSV AE1_N_T_IH0_B_AA2_D_IY0_Z AA1_R P_R_EH1_Z_AH0_N_T IH0_N AE1_N EH1_S_T_AH0_M_EY2_T_AH0_D 54 %  AH1_V CH_IH1_L_D_R_AH0_N AH1_N_D_ER0 DH_AH0 EY1_JH AH1_V    AH0_N_D 77 %  IH0_N CH_IH1_L_D_R_AH0_N OW1_V_ER0 10 Y_IH1_R_Z AH1_V EY1_JH    Algerian CH_IH1_L_D_R_AH0_N AA1_R AO1_L_S_OW0 L_AY1_K_L_IY0 T_UW1 AH0_K_W_AY1_ER0 HSV IH2_N_F_EH1_K_SH_AH0_N AE1_T AH0 Y_AH1_NG EY1_JH    AH1_N_D_ER0    AH0_N_D 81 25 %  AH1_V DH_AH0 P_AA2_P_Y_AH0_L_EY1_SH_AH0_N HH_AE1_Z AE1_N_T_IH0_B_AA2_D_IY0_Z T_UW1 HSV B_AY1 DH_AH0 EY1_JH AH1_V 15    Relative T_UW1 R_EY1_T_S IH0_N Europe AH0_N_D North America    HSV seroprevalency IH1_Z HH_AY1 IH0_N Central AH0_N_D South America Infection L_EH1_V_AH0_L_Z AA1_R EH1_S_T_AH0_M_EY2_T_AH0_D AE1_T 20 %  T_UW1 60     During DH_AH0 M_IH1_D 1980s    HSV P_R_EH1_V_AH0_L_AH0_N_S W_AA1_Z 33 %  IH0_N 25 -  T_UW1 29 Y_IH1_R OW1_L_D W_IH1_M_AH0_N AH0_N_D 45 %  IH0_N DH_OW1_Z EY1_JH_D 40 AH0_N_D OW1_V_ER0 IH0_N Costa Rica In DH_AH0 ER1_L_IY0 1990s HSV P_R_EH1_V_AH0_L_AH0_N_S W_AA1_Z AH0_P_R_AA1_K_S_AH0_M_AH0_T_L_IY0 45 %  AH0_M_AH1_NG W_IH1_M_AH0_N OW1_V_ER0 60 IH0_N Mexico    The HH_AY1_AH0_S_T HSV P_R_EH1_V_AH0_L_AH0_N_S IH0_N Central AO1_R South America 60 %— HH_AE1_Z B_IH1_N F_AW1_N_D IH0_N Colombian M_IH1_D_AH0_L EY1_JH_D W_IH1_M_AH0_N    AO2_L_DH_OW1 S_IH1_M_AH0_L_ER0 HSV P_R_EH1_V_AH0_L_AH0_N_S HH_AE1_Z B_IH1_N AH0_B_Z_ER1_V_D IH0_N Y_AH1_NG_G_ER0 W_IH1_M_AH0_N IH0_N Haiti    54 %     HSV IH2_N_F_EH1_K_T_S AH0_B_AW1_T 30 %  AH1_V W_IH1_M_AH0_N OW1_V_ER0 30 Y_IH1_R_Z OW1_L_D IH0_N Colombia    Costa Rica    Mexico    AH0_N_D Panama HSV AE1_N_T_IH0_B_AA2_D_IY0_Z W_ER1 F_AW1_N_D IH0_N M_AO1_R DH_AE1_N 41 %  AH1_V W_IH1_M_AH0_N AH1_V CH_AY1_L_D_B_EH2_R_IH0_NG EY1_JH IH0_N Brazil    However    N_OW1 IH2_N_K_R_IY1_S IH0_N seroprevalence W_AA1_Z AH0_S_OW1_S_IY0_EY2_T_AH0_D W_IH1_DH EY1_JH IH0_N W_IH1_M_AH0_N OW1_V_ER0 40 Y_IH1_R_Z OW1_L_D IH0_N Brazil HSV P_R_EH1_V_AH0_L_AH0_N_S W_AA1_Z EH1_S_T_AH0_M_EY2_T_AH0_D AE1_T 50 %  AH0_M_AH1_NG W_IH1_M_AH0_N EY1_JH_D 40 49    33 %  AH0_M_AH1_NG W_IH1_M_AH0_N 50 59    AH0_N_D 42 %  AH0_M_AH1_NG W_IH1_M_AH0_N OW1_V_ER0 60 Women IH0_N Brazil AA1_R M_AO1_R L_AY1_K_L_IY0 T_UW1 AH0_K_W_AY1_ER0 AE1_N HSV IH2_N_F_EH1_K_SH_AH0_N IH1_F DH_EH1_R M_EY1_L P_AA1_R_T_N_ER0_Z HH_AE1_D HH_IH1_S_T_ER0_IY0 AH1_V EY1_N_AH0_L S_EH1_K_S AH0_N_D HH_AE1_D M_EH1_N_IY0 S_EH1_K_SH_UW0_AH0_L P_AA1_R_T_N_ER0_Z IH0_N HH_IH1_Z L_AY1_F_T_AY2_M      In Peru    HSV P_R_EH1_V_AH0_L_AH0_N_S IH1_Z AO1_L_S_OW0 HH_AY1 AH0_M_AH1_NG W_IH1_M_AH0_N IH0_N DH_EH1_R 30s B_AH1_T IH1_Z L_OW1_ER0 IH0_N M_EH1_N    HSV seroprevalence IH0_N S_AH1_M Asian K_AH1_N_T_R_IY0_Z IH1_Z L_OW1    R_EH1_L_AH0_T_IH0_V T_UW1 AH1_DH_ER0 K_AH1_N_T_R_IY0_Z W_ER1_L_D_W_AY1_D    W_IH1_DH OW1_N_L_IY0 51 %  W_IH1_M_AH0_N IH0_N Thailand    AH0_N_D B_IH0_T_W_IY1_N 50 60 %  IH0_N Japan P_AH0_Z_EH1_S_IH0_NG AE1_N_T_IH0_B_AA2_D_IY0_Z      HSV seroprevalence IH0_N D_IH0_V_EH1_L_AH0_P_IH0_NG Asian K_AH1_N_T_R_IY0_Z IH1_Z K_AA1_M_P_R_AH0_B_AH0_L    10 30 %   T_UW1 DH_AE1_T AH0_B_Z_ER1_V_D IH0_N North America AH0_N_D Northern Europe    However    EH1_S_T_AH0_M_AH0_T_S AH1_V HSV infectivity IH0_N Thailand AA1_R HH_AY1_ER0 DH_AE1_N AH0_B_Z_ER1_V_D IH0_N AH1_DH_ER0 Eastern Asian K_AH1_N_T_R_IY0_Z ;  T_OW1_T_AH0_L HSV seroprevalence IH1_Z AH0_P_R_AA1_K_S_AH0_M_AH0_T_L_IY0 37 %  IH0_N DH_IH1_S K_AH1_N_T_R_IY0     HSV seroprevalence IH1_Z L_OW1 IH0_N W_IH1_M_AH0_N IH0_N DH_AH0 Philippines    %    AO2_L_DH_OW1 K_AH0_M_EH1_N_S_IH0_NG AE0_K_T_IH1_V_IH0_T_IY0 W_AY1_L Y_AH1_NG IH1_Z AH0_S_OW1_S_IY0_EY2_T_AH0_D W_IH1_DH AE1_N IH2_N_K_R_IY1_S R_IH1_S_K AH1_V AH0_K_W_AY1_R_IH0_NG HSV IH2_N_F_EH1_K_SH_AH0_N ;  W_UH1_M_AH0_N S_T_AA1_R_T_IH0_NG S_EH1_K_SH_UW0_AH0_L AE0_K_T_IH1_V_IH0_T_IY0 B_AY1 DH_AH0 T_AY1_M DH_EY1 R_IY1_CH 17 AA1_R S_EH1_V_AH0_N T_AY1_M_Z M_AO1_R L_AY1_K_L_IY0 T_UW1 B_IY1 HSV seropositive DH_AE1_N DH_OW1_Z S_T_AA1_R_T_IH0_NG S_EH1_K_SH_UW0_AH0_L AE0_K_T_IH1_V_IH0_T_IY0 W_EH1_N OW1_V_ER0 21    In South Korea    IH1_N_S_AH0_D_AH0_N_S AH1_V HSV IH2_N_F_EH1_K_SH_AH0_N IH0_N DH_OW1_Z AH1_N_D_ER0 DH_AH0 EY1_JH AH1_V 20 IH1_Z L_OW1    OW1_N_L_IY0 %  IH0_N M_EH1_N AH0_N_D %  IH0_N W_IH1_M_AH0_N     Seroprevalence L_EH1_V_AH0_L_Z IH2_N_K_R_IY1_S IH0_N OW1_L_D_ER0 South Koreans HH_AW2_EH1_V_ER0    S_AH1_CH DH_AE1_T DH_AH0 P_AA2_P_Y_AH0_L_EY1_SH_AH0_N OW1_V_ER0 20 DH_AE1_T HH_AE1_Z AE1_N_T_IH0_B_AA2_D_IY0_Z AH0_G_EH1_N_S_T HSV IH1_Z 21 %  AH1_V M_EH1_N AH0_N_D 28 %  AH1_V W_IH1_M_AH0_N    In India 33 %  AH1_V IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z AA1_R seropositive F_AO1_R HSV AH0_N_D 16 %  AA1_R seropositive F_AO1_R HSV Those W_IH1_DH B_OW1_TH HSV AH0_N_D HSV AE1_N_T_IH0_B_AA2_D_IY0_Z AA1_R EH1_S_T_AH0_M_EY2_T_AH0_D AE1_T 13 %  AH1_V DH_AH0 P_AA2_P_Y_AH0_L_EY1_SH_AH0_N Indian M_EH1_N AA1_R M_AO1_R L_AY1_K_L_IY0 T_UW1 B_IY1 IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV DH_AE1_N W_IH1_M_AH0_N    AH0_N_D IH2_N_K_R_IY1_S_IH0_NG seroprevalence AH1_V DH_IH1_S V_AY1_R_AH0_S IH1_Z AH0_S_OW1_S_IY0_EY2_T_AH0_D W_IH1_DH AE1_N IH2_N_K_R_IY1_S_IH0_NG EY1_JH    Turkey —  High L_EH1_V_AH0_L_Z AH1_V HSV    97 %   AH0_N_D HSV    42 %   W_ER1 F_AW1_N_D AH0_M_AH1_NG_S_T P_R_EH1_G_N_AH0_N_T W_IH1_M_AH0_N IH0_N DH_AH0 S_IH1_T_IY0 AH1_V Erzurum IH0_N Eastern Anatolia Region    Turkey    In Istanbul HH_AW2_EH1_V_ER0    L_OW1_ER0 HSV seroprevalence W_AA1_Z AH0_B_Z_ER1_V_D ;  HSV AE1_N_T_IH0_B_AA2_D_IY0_Z W_ER1 F_AW1_N_D IH0_N %  AH1_V S_EH1_K_SH_UW0_AH0_L_IY0 AE1_K_T_IH0_V AH0_D_AH1_L_T_S    W_AY1_L HSV AE1_N_T_IH0_B_AA2_D_IY0_Z W_ER1 F_AW1_N_D IH0_N 85    Only %  AH1_V P_R_EH1_G_N_AH0_N_T W_IH1_M_AH0_N W_ER1 IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV    AH0_N_D 98 %  W_ER1 IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV    Prevalence AH1_V DH_IY1_Z V_AY1_R_AH0_S_AH0_Z W_AA1_Z HH_AY1_ER0 IH0_N S_EH1_K_S W_ER1_K_ER0_Z AH1_V Istanbul    R_IY1_CH_IH0_NG L_EH1_V_AH0_L_Z AH1_V 99 %  AH0_N_D 60 %  F_AO1_R HSV AH0_N_D HSV P_R_EH1_V_AH0_L_AH0_N_S R_IH0_S_P_EH1_K_T_IH0_V_L_IY0    Jordan —  The P_R_EH1_V_AH0_L_AH0_N_S AH1_V HSV IH0_N Jordan IH1_Z 52 %  F_AO1_R M_EH1_N AH0_N_D 41 %  F_AO1_R W_IH1_M_AH0_N    Israel —  HSV seroprevalence IH1_Z 59 %  IH0_N DH_AH0 P_AA2_P_Y_AH0_L_EY1_SH_AH0_N AH1_V Israel AH0_N_D IH2_N_K_R_IY1_S_IH0_Z W_IH1_DH EY1_JH IH0_N B_OW1_TH JH_EH1_N_D_ER0_Z B_AH1_T DH_AH0 AE2_D_AH0_L_EH1_S_AH0_N_T seroprevalence HH_AE1_Z B_IH1_N D_IH0_K_L_AY1_N_IH0_NG AE1_Z IH0_N M_OW1_S_T IH2_N_D_AH1_S_T_R_IY0_AH0_L_AY2_Z_D N_EY1_SH_AH0_N_Z    An EH1_S_T_AH0_M_EY2_T_AH0_D %  AH1_V Israeli AH0_D_AH1_L_T_S AA1_R IH2_N_F_EH1_K_T_IH0_D W_IH1_DH HSV Infection AH1_V IY1_DH_ER0 HSV AO1_R HSV IH1_Z HH_AY1_ER0 IH0_N F_IY1_M_EY2_L_Z ;  HSV seroprevalence R_IY1_CH_AH0_Z 20 %  IH0_N F_IY1_M_EY2_L_Z IH0_N DH_EH1_R 40s These V_AE1_L_Y_UW0_Z AA1_R S_IH1_M_AH0_L_ER0 T_UW1 L_EH1_V_AH0_L_Z IH0_N HSV IH2_N_F_EH1_K_SH_AH0_N IH0_N Europe    Antibodies F_AO1_R HSV AO1_R HSV AA1_R AO1_L_S_OW0 M_AO1_R L_AY1_K_L_IY0 T_UW1 B_IY1 F_AW1_N_D IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z B_AO1_R_N AW1_T_S_AY1_D AH1_V Israel    AH0_N_D IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z R_IH0_Z_AY1_D_IH0_NG IH0_N Jerusalem AH0_N_D Southern Israel ;  P_IY1_P_AH0_L AH1_V Jewish AO1_R_AH0_JH_AH0_N L_IH1_V_IH0_NG IH0_N Israel AA1_R L_EH1_S L_AY1_K_L_IY0 T_UW1 P_AH0_Z_EH1_S AE1_N_T_IH0_B_AA2_D_IY0_Z AH0_G_EH1_N_S_T HH_ER1_P_IY0_Z    Among P_R_EH1_G_N_AH0_N_T W_IH1_M_AH0_N IH0_N Israel AH0 S_M_AO1_L S_K_EY1_L K_R_AO1_S S_EH1_K_SH_AH0_N_AH0_L S_T_AH1_D_IY0 F_AW1_N_D DH_AH0 P_R_EH1_V_AH0_L_AH0_N_S AH1_V HSV IH2_N_F_EH1_K_SH_AH0_N W_AA1_Z 13 %  AH0_N_D DH_AE1_T AH1_V HSV W_AA1_Z 94 The HSV IH2_N_F_EH1_K_SH_AH0_N R_EY1_T W_AA1_Z F_OW1_L_D HH_AY1_ER0 AH0_M_AH1_NG IH1_M_AH0_G_R_AH0_N_T_S F_R_AH1_M DH_AH0 F_AO1_R_M_ER0 Soviet Union    27 %   DH_AE1_N AH0_M_AH1_NG Israeli B_AO1_R_N Jewish AH0_N_D Arab W_IH1_M_AH0_N    %     Approximately 78 %  AH1_V HSV IH2_N_F_EH1_K_SH_AH0_N_Z IH0_N Israel AA1_R EY2_S_IH2_M_P_T_AH0_M_AE1_T_IH0_K    HSV K_AA1_Z_AH0_Z 66 %  AH1_V JH_EH1_N_AH0_T_AH0_L HH_ER1_P_IY0_Z IH0_N DH_AH0 Tel Aviv EH1_R_IY0_AH0    Syria —  Genital HH_ER1_P_IY0_Z IH2_N_F_EH1_K_SH_AH0_N F_R_AH1_M HSV IH1_Z P_R_IH0_D_IH1_K_T_IH0_D T_UW1 B_IY1 L_OW1 IH0_N Syria AO2_L_DH_OW1 HSV L_EH1_V_AH0_L_Z AA1_R HH_AY1 HSV IH2_N_F_EH1_K_SH_AH0_N_Z IH1_Z K_AA1_M_AH0_N    95 %   AH0_M_AH1_NG HH_EH1_L_TH_IY0 Syrians OW1_V_ER0 DH_AH0 EY1_JH AH1_V 30    W_AY1_L HSV P_R_EH1_V_AH0_L_AH0_N_S IH1_Z L_OW1 IH0_N HH_EH1_L_TH_IY0 IH2_N_D_AH0_V_IH1_JH_AH0_W_AH0_L_Z    15 %    AH0_N_D P_ER1_S_AH0_N_Z IH2_N_F_EH1_K_T_IH0_D W_IH1_DH AH1_DH_ER0 S_EH1_K_SH_UW0_AH0_L_IY0 T_R_AE0_N_S_M_IH1_T_IH0_D D_IH0_Z_IY1_Z_AH0_Z    %     High R_IH1_S_K G_R_UW1_P_S F_AO1_R AH0_K_W_AY1_R_IH0_NG HSV IH0_N Syria    IH2_N_K_L_UW1_D P_R_AA1_S_T_AH0_T_UW2_T_S AH0_N_D B_AA1_R G_ER1_L_Z ;  DH_EY1 HH_AE1_V 34 %  AH0_N_D 20 %  seroprevalence R_IH0_S_P_EH1_K_T_IH0_V_L_IY0    In Australia    AH0 S_T_AH1_D_IY0 Y_UW1_Z_IH0_NG D_EY1_T_AH0 F_R_AH1_M 1999 R_IH0_V_IY1_L_D DH_AH0 seroprevalence AH1_V HSV W_AA1_Z AE1_T 76 %   W_IH1_DH S_AH0_G_N_IH1_F_IH0_K_AH0_N_T D_IH1_F_ER0_AH0_N_S_IH0_Z AH0_S_OW1_S_IY0_EY2_T_AH0_D W_IH1_DH EY1_JH    JH_EH1_N_D_ER0 AH0_N_D Indigenous S_T_AE1_T_AH0_S    W_IH1_CH W_ER1 N_AA1_T S_P_EH1_S_AH0_F_AY2_D     An EH1_S_T_AH0_M_EY2_T_AH0_D 12 %  AH1_V Australian AH0_D_AH1_L_T_S W_ER1 seropositive F_AO1_R HSV    W_IH1_DH HH_AY1_ER0 P_R_EH1_V_AH0_L_AH0_N_S IH0_N W_IH1_M_AH0_N    16 %   DH_AE1_N IH0_N M_EH1_N    %     Larger S_IH1_T_IY0_Z HH_AE1_D HH_AY1_ER0 HSV seroprevalence    13 %   DH_AE1_N R_UH1_R_AH0_L P_AA2_P_Y_AH0_L_EY1_SH_AH0_N_Z    %  Higher P_R_EH1_V_AH0_L_AH0_N_S W_AA1_Z F_AW1_N_D IH0_N Indigenous Australians    18 %   DH_AE1_N N_AA1_N Indigenous Australians    12 %     As IH0_N DH_AH0    HSV IH1_Z IH2_N_K_R_IY1_S_IH0_NG_G_L_IY0 AY0_D_EH1_N_T_AH0_F_AY2_D AE1_Z DH_AH0 K_AA1_Z AH1_V    JH_EH1_N_AH0_T_AH0_L HH_ER1_P_IY0_Z IH0_N Australians ;  HSV W_AA1_Z AY0_D_EH1_N_T_AH0_F_AY2_D IH0_N DH_AH0 anogenital EH1_R_IY0_AH0 AH1_V OW1_N_L_IY0 %  AH1_V DH_AH0 P_AA2_P_Y_AH0_L_EY1_SH_AH0_N IH0_N 1980    B_AH1_T HH_AE1_D R_IH1_Z_AH0_N T_UW1 41 %  IH0_N 2001    This W_AA1_Z M_OW1_S_T K_AA1_M_AH0_N IH0_N F_IY1_M_EY2_L_Z AH0_N_D P_ER1_S_AH0_N_Z AH1_N_D_ER0 25    The N_AH1_M_B_ER0 AH1_V JH_EH1_N_AH0_T_AH0_L HH_ER1_P_IY0_Z IH2_N_F_EH1_K_SH_AH0_N_Z AH0_P_IH1_R_Z T_UW1 B_IY1 R_AY1_Z_IH0_NG IH0_N New Zealand W_IH1_DH TH_R_IY1 T_AY1_M_Z M_AO1_R K_EY1_S_AH0_Z IH0_N 1993 K_AH0_M_P_EH1_R_D T_UW1 1977    In DH_IH1_S K_AH1_N_T_R_IY0    HSV AH0_F_EH1_K_T_S 60 %  M_AO1_R W_IH1_M_AH0_N DH_AE1_N M_EH1_N AH1_V S_IH1_M_AH0_L_ER0 EY1_JH   